Clinical Impact of New Rheumatoid Arthritis Findings From EULAR 2020*

Download All
June 3-6, 2020; Virtual Meeting
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from EULAR 2020.
Paul Emery, MA, MD, FRCP
Eric M. Ruderman, MD

Rheumatoid Arthritis Highlights From EULAR 2020

Slidesets Infection Incidence With Upadacitinib in Patients With Rheumatoid Arthritis
Slidesets SRQ: VTE Risk Increases Alongside Disease Activity Among Swedish Patients With Rheumatoid Arthritis
Slidesets Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases
Slidesets JAK-POT: Real-World Risk of Treatment Discontinuation Across 17 International Registers of Patients With Rheumatoid Arthritis
Slidesets WHO VigiBase Analysis: Thromboembolic Safety of Tofacitinib, Baricitinib in Rheumatoid Arthritis
Slidesets RABBIT: Risk of Herpes Zoster Stratified by DMARD Type Among Patients With Rheumatoid Arthritis
Slidesets SELECT-CHOICE: Upadacitinib vs Abatacept in Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to bDMARDs
Slidesets FINCH 1: 52-Wk Results of Filgotinib in Patients With Rheumatoid Arthritis With Inadequate Response to Methotrexate

My take on the most important findings in RA prevention and treatment presented at the virtual EULAR 2020 E-Congress.

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: July 16, 2020 Expired: July 15, 2021

My take on the most important findings regarding efficacy and safety of JAK inhibitors in RA presented at the virtual EULAR 2020 E-Congress.

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: July 16, 2020 Expired: July 15, 2021

My thoughts on recent studies of RA and ILD, fatigue, and cancer presented at the virtual EULAR 2020 E-Congress.

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: August 24, 2020 Expired: August 23, 2021

What to do in biologic-experienced patients with RA? Here’s my take.

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: August 27, 2020 Expired: August 26, 2021
Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue